NEW YORK: Glycotest, Inc., a diagnostics company commercializing new and unique blood tests for life threatening liver cancers and fibrosis-cirrhosis, has received the second $3 million tranche of the $10 million Series A financing round from Shanghai Fosun Pharmaceutical Co., Ltd. The focus of this strategic investment is the advancement of the HCC Panel toward…